There is overwhelming public interest to support COVID-19 vaccine development. In fact many have already done this. As the UK gears up to participate in its third vaccine study called ENSEMBLE, a Phase 3 clinical trial with the Janssen developed Ad26-vectored vaccine candidate shortly with participants drawn from the NHS vaccines registry, the lack of transparent participant information is surprising. To date, I’ve yet to see one. Granted, I’ve never scrutinized a vaccine study before, but surely the same regulations apply here as for other clinical trials?
With that in mind are you surprised if I said that Janssen had to temporarily halt development in the US due to an adverse reaction? What adverse reaction you may wonder, I wondered also ever since Oct 11 after recruitment was paused, and continue to wander:
“A trial of another vaccine, being developed by Johnson & Johnson, was paused on Oct. 11. According to a person familiar with the matter, a male volunteer in his twenties had a cerebral haemorrhage and transverse sinus venous thrombosis. The Washington Post, citing two sources, said this case was a stroke.” STAT news, Oct 23.
Intellectual property be damned, where are the peer-reviewed case publications detailing point by point what went wrong with these vaccines? Surely, this is also of paramount importance to the public? Accountability even. We have no right to poke fun at the Russians, when we are behaving in a similar fashion in the West.